BioMérieux: price target raised by Invest Securities

(CercleFinance.com) - Invest Securities has reiterated its 'buy' rating on bioMérieux, with the target price raised from €126 to €130, continuing to target the high end of the in vitro diagnostics company's guidance, which it considers 'perfectly achievable'.


'As in recent publications, third-quarter growth came in above expectations, underpinned by an outperformance from the molecular biology franchise', notes the analyst, satisfied with the growth in growth drivers.

Despite the slight advance over nine months, the company is reiterating its 2024 targets, which we believe to be coherent, as the fourth quarter is likely to be less dynamic, unless the intensity of the flu epidemic increases", he continues.

Copyright (c) 2024 CercleFinance.com. All rights reserved.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.